3 Lesser-Known Biotech Stocks That Are Surging

Earlier this month, the company launched its new five-Year Strategy, called Alnylam P5x25, for its planned transition to be among the top-five biotechs by market capitalization over the next five years. The company also announced full-year 2020 preliminary global net product revenues for ONPATTRO® and GIVLAARI® at nearly $306 million and $55 million, respectively.

Analysts expect revenue for the quarter ended December 31, 2020, to rise 104.5% year-over-year to $146.6 million. Meanwhile, its EPS is likely to expand at the rate of 46.1% per annum over the next five years.

ALNY ended yesterday’s trading session at $168.41, climbing 41.7% over the past year. During the past six months, the stock has risen 6.4%.

ANLY is rated “Strong Buy” with an “A” for Trade Grade, Buy & Hold Grade, Peer Grade, and a “B” for Industry Rank. It is currently ranked #6 of 483 stocks in the Biotech Industry.

Zai Lab Limited (ZLAB - Get Rating)

ZLAB is a biotechnology company involved in discovering, developing, licensing, and commercializing proprietary therapeutics to provide treatment in oncology, infectious, and l  autoimmune diseases in China.  The company’s oral small molecule poly ADP ribose polymerase 1/2 inhibitor, Niraparib, is used to treat multiple solid tumors and ovarian and lung cancer.

ZLAB announced the expansion of its collaboration with Turning Point Therapeutics (TPTX), a precision oncology company. Under the agreement, ZLAB would obtain exclusive rights to develop and commercialize TPTX’s MET, SRC, and CSF1R inhibitor, TPX-0022, in Greater China. TPTX will receive a $25 million upfront payment, with up to nearly $336 million in potential development, regulatory, and sales-based milestone payments.

For the six months ended June 2020, ZLAB’s revenue has surged 461.8% year-over-year to $19.2 million, driven by the sales of ZEJULA, which was launched in January 2020. Meanwhile, its loss per share narrowed to $1.37 from $1.74 posted in the same period last year.

View single page >> |

Disclaimer: Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use, please ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.